Evidence from both preclinical and clinical studies supports the cardioprotective role of SGLT2 inhibitors in managing cancer therapy-related cardiovascular toxicity (CTR-CVT), particularly that associated with anthracyclines, immune checkpoint inhibitors, and HER2-targeted agents. The gene discussed is SLC5A2; the disease is cancer.